4.8 Article

Interaction of BARD1 and HP1 Is Required for BRCA1 Retention at Sites of DNA Damage

期刊

CANCER RESEARCH
卷 75, 期 7, 页码 1311-1321

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-14-2796

关键词

-

类别

资金

  1. Japan Society for the Promotion of Science
  2. Ministry of Education, Science, Sports, Culture and Technology of Japan
  3. Ministry of Health, Labour and Welfare of Japan
  4. Japan Private School Promotion Foundation
  5. National Institute of General Medical Sciences grants [R01 GM088055]
  6. PHS NRSA [2T32 GM007270]
  7. Grants-in-Aid for Scientific Research [26670730, 26290042, 24112005] Funding Source: KAKEN

向作者/读者索取更多资源

Stable retention of BRCA1/BARD1 complexes at sites of DNA damage is required for the proper response to DNA double-strand breaks (DSB). Here, we demonstrate that the BRCT domain of BARD1 is crucial for its retention through interaction with HP1. In response to DNA damage, BARD1 interacts with Lys9-dimethylated histone H3 (H3K9me2) in an ATM-dependent but RNF168-independent manner. This interaction is mediated primarily by HP1 gamma. A conserved HP1-binding motif in the BARD1 BRCT domain directly interacted with the chromoshadow domain of HP1 in vitro. Mutations in this motif (or simultaneous depletion of all three HP1 isoforms) disrupted retention of BARD1, BRCA1, and CtIP at DSB sites and allowed ectopic accumulation of RIF1, an effector of nonhomologous end-joining, at damaged loci in S-phase. UNC0638, a small-molecule inhibitor of histone lysine methyltransferase (HKMT), abolished retention and cooperated with the PARP inhibitor olaparib to block cancer cell growth. Taken together, our findings show how BARD1 promotes retention of the BRCA1/BARD1 complex at damaged DNA sites and suggest the use of HKMT inhibitors to leverage the application of PARP inhibitors to treat breast cancer. (C)2015 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据